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18.1  Introduction
Phototoxicity and photoallergy are different expressions 
of an abnormal skin reaction from the exposure to light, 
usually enhanced by endogenous or exogenous sub-
stances that are selectively activated by solar radiation.
This can occur with artificial light sources (sun 
lumps used for aesthetic or therapeutic purposes or 
ultraviolet (UV) sources in occupational settings), but 
mostly occur on sun exposure. From the solar spec-
trum that reaches the earth, UV radiation, and particu-
larly UVA (320–400 nm), is responsible for most cases 
of photosensitivity. Even though some chromophores 
absorb in the UVB (290–320 nm) and UVB is more 
energetic, UVA penetrates the skin more deeply and, 
particularly for systemic chromophores, this is cer-
tainly the most important spectrum for inducing photo-
dermatosis [1]. Only exceptional reports have a well- 
documented exogenous photosensitivity exclusively 
from UVB [2].
Photosensitivity from topical agents, once frequent 
and often associated with persistent reactions to light, is 
now becoming rare [3, 4], as the main topical photosen-
sitizers are removed from the market, or maybe photo-
sensitivity is underreported or underdiagnosed [5]. On 
the other hand, and even though sun avoidance is rec-
ommended in those exposed to known photosensitizers, 
new drugs are reported to have photosensitizing proper-
ties, eventually associated with late problems.
Therefore, photosensitivity is still a problem and a 
field on intense research. New photosensitizers are 
reported as a cause of skin disease, whereas others are 
used for phtnototherapy. Studies are still being under-
taken on the mechanisms and chromophores, respon-
sible for diseases associated with photosensitivity, 
such as HIV infection [6, 7].
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18.2  General Mechanisms  
of Photosensitivity
Normal skin has several molecules that are activated 
upon sun exposure and undergo chemical reactions – 
the chromophores – which are important for our sur-
vival under the sun and necessary for our life. An 
example is 7-dehydrocholesterol which, upon activa-
tion by UVB, forms provitamin D3 necessary for 
Vitamin D synthesis.
Photosensitivity develops when an abnormal chro-
mophore, or a normal chromophore in exaggerated 
amounts, is present in the skin. When excited by a photon, 
these molecules suffer changes within the molecule itself, 
often also within neighboring molecules, in a cascade of 
events that result in skin damage and inflammation. This 
can occur through the direct molecular modification 
(isomerization, breaking of double bounds, oxidation) or 
production of free radicals, dependent or not on oxygen, 
which modify unsaturated lipids of cell membranes, aro-
matic amino acids of proteins, or DNA or RNA bases of 
nucleic acids. If the repair mechanisms do not act imme-
diately, there is damage and/or death of skin cells and 
inflammatory mediators are produced (prostaglandins, 
IL-1, 6, 8, other cytokines, and chemokines) with conse-
quent skin lesions – this is briefly the mechanism of pho-
totoxicity [1]. In some circumstances, the energy of the 
photon can be used by the chromophore to transform 
itself into a new molecule (photoproduct) or to bind an 
endogenous peptide and, therefore, form a hapten or an 
allergen that can be recognized by the skin immune sys-
tem. In these cases, photoallergy may develop with a sen-
sitization phase and effector phase similar to allergic 
contact dermatitis (see Chap. 8 for more details).
Apart from the capacity to generate free radicals 
responsible for phototoxicity, several phototoxic sub-
stances, such as psoralens, chlorpromazine, and fluo-
rquinolones, have shown to induce chromosomal 
damage in the presence of UVR. Therefore, both in vitro 
and in animal studies, they were photomutagenic and 
photoimmunosuppressive, with consequent implica-
tions in photocarcinogenesis [8–12]. Epidemiological 
studies and recent reports are showing this may also be 
significant for humans. In 1999, the group of Przybilla 
showed an association between actinic keratosis and the 
use of potentially photosensitizing chemicals [13]. More 
recent data tend to confirm an increased risk in patients 
on long-term PUVA treatments [14] and, also in those 
exposed to fluorquinolones, diuretics [15], and voricon-
azole [16]. The chromophore responsible for the photo-
sensitive reaction can be an endogenous molecule, like 
a porphyrin that accumulates in the skin due to an inborn 
metabolic error, or it can be an exogenous molecule that 
is applied on the skin or reaches the skin through the 
systemic circulation. In many diseases, the chromophore 
has been identified, but there are many idiopathic photo-
dermatoses for which the main chromophore is still 
unknown. Some resemble exogenous photoallergic 
reactions, like “Lucite Estivale Bénigne,” polymorphic 
light eruption, or chronic actinic dermatitis, whereas 
others have very typical clinical patterns, like hydroa 
vacciniforme or actinic prurigo. Also, as sunscreens are 
widely used to prevent skin lesions in these photoder-
matoses, these patients frequently develop allergic or 
photoallergic contact dermatitis to UV filters [3, 4], 
thereby associating the effect of endogenous and exog-
enous chromophores.
In some patients, photosensitivity develops because 
of a deficiency in the capacity to repair UV aggression, 
due to a genetic problem (xeroderma pigmentosum, 
Bloom’s syndrome) or a transient imbalance of antioxi-
dant skin defense (in pellagra due to reduced levels of 
niacin in diet or alcohol consumption), or because the 
natural mechanisms of skin protection are deficient (vit-
iligo, albinism) [1, 17].
18.2.1  Phototoxicity vs. Photoallergy
In theory, it is easy to differentiate photoallergy, a 
T-cell-mediated hypersensitivity reaction to an aller-
gen formed upon UV exposure, from phototoxicity, 
that represents an exaggerated inflammatory response 
to the sun enhanced by an exogenous chromophore. 
Classically, photoallergy develops only in a limited 
number in individuals, needs previous sensitization but 
is extensive to cross-reactive chemicals, is subject to 
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18 Phototoxic and Photoallergic Reactions 
flare-ups, is not dependent on the dose of the exoge-
nous chromophore and needs low UV exposure, 
appears as eczema that can spread to nonexposed sites, 
and on skin biopsy, there is mainly spongiosis as in 
eczema. Phototoxicity is more frequent and considered 
to develop in every individual, as long as enough pho-
tosensitizer and sun exposure are present; occurs even 
on a first and single contact, with no flare-ups or cross-
reactions; and appears mainly as well-demarcated ery-
thema exclusively on sun-exposed areas (mimicking 
sunburn); and on histology, apoptotic keratinocytes 
(sunburn cells) are abundant (Table 18.1).
But, even though there are typical aspects of these 
two polar types of photosensitivity, some molecules 
may induce both phototoxic and photoallergic dermati-
tis. Although rare, this can occur with plant furocou-
marins (Ruta graveolans, Ficus carica, Umbeliferae) 
or during photochemotherapy, as individuals become 
reactive to very low concentrations of psoralens [18]. 
Also, for mainly phototoxic drugs like promethazine 
and lomefloxacin, a few patients develop photoallergy, 
reacting to very low doses of the drug or sun exposure 
[19–21]. Most probably, as occurs with contact aller-
gens that have an inherent “irritant” potential to awaken 
the innate immune system necessary to promote the 
sensitization process [22], photoallergens are photoac-
tive molecules with some inherent phototoxicity, which 
may be the “danger signal” necessary to initiate the 
sensitizing process.
Also, although it is considered that photoallergy does 
not occur on a first contact due to the need for previous 
sensitization, this may not be necessary if you have 
already been sensitized by contact to a similar molecule. 
This occurs in patients who are allergic to thiomersal, 
namely to its moiety thiosalicylic acid, who develop 
photosensitivity to piroxicam on the first intake of the 
drug. Upon UVA irradiation, piroxicam is photodecom-
posed into a molecule very similar antigenically and 
structurally to thiosalicylic acid, responsible for piroxi-
cam photoallergy [23–25].
Also, although phototoxicity is considered to occur 
in every patient as long as enough chromophore and 
sun are present at the same time, there is also individual 
susceptibility to phototoxicity from drugs and phyto-
photodermatitis, even though the parameters that char-
acterize this susceptibility are not precisely known.
Therefore, and although, in theory, we can separate 
these two mechanisms – phototoxicity and photoal-
lergy, there is often an overlap between both.
18.3  Clinical Patterns  
of Photosensitivity
The clinical patterns of photosensitive disorders are 
sometimes very typical, like phytophotodermatitis, acute 
exaggerated sunburn from exposure to a phototoxic 
Phototoxicity Photoallergy
Frequency High Low
Latency period/sensitization No Yes
Doses of UV/photosensitizer High Low
Cross-reactions No Yes
Morphology of lesions Sunburn, polymorphic Eczema, erythema multiforme
Sharp limits Yes No
Covered areas Not involved Possibly involved
Resolution Quick May recur, persistent reactors
Residual hyperpigmentation Yes No





Table 18.1 Distinction between phototoxicity and photoallergy








































































drug, and, among some idiopathic photodermatoses, 
hydroa vacciniforme and xeroderma pigmentosum. But, 
sometimes, the diagnosis or even the suspicion of photo-
sensitivity is not so obvious. It is the example of acute or 
chronic eczematous skin lesions, extending to covered 
areas, with a less well-established relation with sun 
exposure (often a regular exposure), like in chronic 
actinic dermatitis or in photoaggravation of rosacea or 
lupus erythematosus by sunscreens.
The clinical manifestations of photosensitivity are 
very polymorphic (Table 18.2), extending from urti-
caria through eczema or subacute lupus erythematosus 
up to vitiligo-like lesion or squamous cell carcinomas 
[14, 16, 19].
In some cases, exposure to sun induces immediate 
reactions, like in solar urticaria, but the appearance of 
skin lesions may be delayed 1 or 2 days, as in photoal-
lergic contact dermatitis or systemic photoallergy, sev-
eral days or weeks, as in pseudoporphyria or subacute 
lupus erythematosus, or even years, as in photocar-
cinogenesis enhanced by a long exposure to the sun 
and photoactive drugs.
Localization of the lesions in photosensitivity from 
a topical agent draws the area of application and con-
comitant sun exposure. But localization and distribu-
tion of lesions may be more peculiar extending to areas 
of accidental contact, as in a contra-lateral limb (kiss-
ing faces of the legs) or areas of inadvertent spread by 
the hands or other contaminated objects [26]. Also, as 
some topical drugs are absorbed through the skin 
(NSAIDs), the distribution of the lesions can be simi-
lar to systemic photosensitivity. This is usually very 
typical, as the reaction frequently involves, in a sym-
metric distribution, all exposed areas of the face, the 
V-shaped area of the neck, and upper chest, dorsum of 
the hands and forearms, while shaded areas are spared. 
This corresponds, in the face, to the upper eyelids, 
upper lip, deep wrinkles (Fig. 18.1), retroauricular 
areas, submandibular area (Fig. 18.2), and areas cov-
ered by the beard or hair; and in the body, to the large 
body folds, like the axillae, groins, finger webs, and to 
all the areas covered by clothing or other accessories 
(watch strip, shoes). This allows a distinction from air-
borne dermatitis where the allergen in the environment 
can localize in these shaded areas and induce skin 
lesions, without the need for sun exposure.
In exceptional cases where sun exposure is asym-
metric, this pattern can be different, as in car drivers 
who only expose the left arm. Sometimes, in systemic 
photosensitivity, the lower lip is mainly or almost 
exclusively involved, because of its higher exposure 
and, most probably, because of the lower thickness of 
the corneal layer, which is one of the main defenses 





Exaggerated “sunburn” Urticaria of sun exposed area








Subacute or chronic lupus 
erythematosus
Actinic keratosis and 
squamous cell carcinoma
Pellagra like-reactions
Table 18.2 Clinical patterns of photosensitivity[AU2]
Fig. 18.1 Acute phototoxicity from amiodarone, mimicking sun-




































































18 Phototoxic and Photoallergic Reactions 
18.3.1  Acute Manifestations  
of Photosensitivity
18.3.1.1  Immediate Reactions
Apart from idiopathic solar urticaria, for which a chro-
mophore is not identified, urticaria as a manifestation 
of photosensitivity from an exogenous substance has 
been rarely described with 5-aminolevulinic acid, used 
in photodynamic therapy [30], with oxybenzone [31, 
32] and chlorpromazine [33]. Nevertheless for some 
drugs, like amiodarone and benoxaprofen (already 
removed from the market), immediate prickling and 
burning with transient erythema may occur as a mani-
festation of photosensitivity [14].
18.3.1.2  Acute Phototoxicity, Mimicking 
Sunburn
The main acute clinical manifestation of phototoxic-
ity is a well-demarcated acute erythema or edema 
with prickling and burning, eventually progressing to 
bullae with skin pain, which develops within 12–24 h 
of sun exposure. This gives rise to large sheets of epi-
dermal detachment within the next days and can 
resolve with residual hyperpigmentation. This is simi-
lar to exaggerated sunburn (Fig. 18.1), and eventually, 
can also be associated with systemic symptoms like 
fever.
18.3.1.3  Acute Photoallergic Eczema
Photoallergy occurs usually as a pruritic eczematous 
reaction of the sun exposed areas, with irregular limits, 
often extending to covered areas. It develops more than 
24–48 h after sun exposure, and not on a first contact. 
This resolves, like in acute eczema, with desquamation 
and no hyperpigmentation. Distribution of lesions is 
usually symmetric in systemic photosensitivity and 
shaded areas are also protected but not as sharply as in 
phototoxicity (Fig. 18.2).
In the more intense photoallergic reactions, typical 
or atypical target lesions, characteristic of erythema 
multiforme and with histopathology of erythema mul-
tiforme, can be seen in association with the eczema-
tous plaques, mainly at its limits or at distant sites, as 
was described for ketoprofen [34, 35]
In some cases, a systemic photosensitizer can induce 
a photodistributed erythema multiforme or toxic epi-
dermal necrolysis, as described with paclitaxel [36], 
naproxen [37] and clobazam [38].
18.3.2  Subacute Manifestations  
of Photosensitivity
Other less frequent clinical patterns develop with a 
delay of days/weeks after exposure to the photosensi-
tizer and the sun, or rarely acutely. These patterns that 
Fig. 18.2 Acute eczema from systemic piroxicam, sparing the 
submandibular shaded area
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evoke mainly a phototoxic reaction are pseudoporphy-
ria,  photoonycholysis, hyper or hypopigmentation, 
telangiectasia, and purpura.
18.3.2.1  Pseudoporphyria
Pseudoporphyria with chronic skin fragility and flac-
cid bullae on noninflamed sun-exposed skin, occasion-
ally with later milia formation, mimicking porphyria 
cutanea tarda on clinical and histopathology (bullae 
formation below the lamina densa), was described ini-
tially for nalidixic acid, furosemide, and naproxen, 
predominantly in children [14, 39] and, more recently, 
for ciprofloxacin [40], celecoxib [41, 42], voriconazole 
[28, 43], and imatinib [44]. This may represent a typi-
cal phototoxic reaction where the drug, as the chro-
mophore, has a similar mechanism of inducing the 
phototoxic reaction (singlet oxygen) as the uroporphy-
rin in the hereditary disease [14, 39].
18.3.2.2  Photoonycholysis
Photoonycholysis, with a half moon distal onycholysis 
of one or several nails, is a typical pattern of phototox-
icity and often the single manifestation of this reaction. 
It appears late (2–3 weeks after drug intake and sun 
exposure), may be preceded by pain in the nail appara-
tus, and occurs mainly with tetracyclines (demethyl-
chlortetracyclie or doxycycline) [45], psoralens, and 
fluorquinolones [46]. There is no definite explanation 
for the single involvement of the nail: the nail bed is 
relatively unprotected from sunlight, contains less mel-
anin, the nail plate may work as a lens, and the inflam-
matory reaction induces detachment of the nail plate 
from the nail bed [45–47].
18.3.2.3  Dyschromia
Hyperpigmentation that follows mainly an acute pho-
totoxic reaction is frequently due to the residual mel-
anocytic hyperpigmentation, and is very typical in 
phytophotodermatitis, or after lichenoid reactions, e.g., 
from phenothiazines (Fig. 18.3).
In rare occasions, like those induced by flutamide, 
vitiliginous lesions with sharp limits occur after the 
acute photosensitive reaction [48, 49].
Hyperpigmentation, or more precisely dyschromia, 
may occur from the accumulation of the drug or drug 
metabolites in the dermis, namely from amiodarone, 
minocycline, and phenothiazines [50, 51]. Apart from 
acute photosensitivity reaction that occurs more fre-
quently, a smaller percentage of these patients, mainly 
those with lower phototypes, develop a golden-brown, 
slate gray, or bluish color on sun-exposed areas. This 
discoloration develops later and persists much longer 
than residual melanocytic hyperpigmentation [14, 50] 
(Fig. 18.4).
18.3.2.4  Other Clinical Patterns
Telangiectasia as a manifestation of photosensitivity has 
been reported with calcium channel blockers [52] and 
the telangiectatic pattern of photoaging with lesions 
mainly in the lateral folds of the neck, sparing the shaded 
Fig. 18.3 Lichenoid lesions and pigmentation in the photoex-

























































18 Phototoxic and Photoallergic Reactions 
a
b
Fig. 18.4 Chronic phototox-
icity in a patient on a 
long-term treatment with 
minocycline. Note the 
lichenification, with ectropion 
and the brownish pigmenta-
tion (a) and onycholysis in  
all his fingers (b). Photo-
onycholysis can occur as an 
isolated manifestation of 
photosensitivity
skin under the chin, is frequently observed in patients 
chronically exposed to photoactive drugs. In rare cases, 
petechial purpura with sharp limits on shaded areas was 
described with ciprofloxacin [53].
Pellagra is associated with the prolonged use of iso-
niazid, which consumes niacin for its metabolization, 
and pellagroid reactions were reported with anticancer 











18.3.3  Delayed and Late Effects  
of Photosensitivity
18.3.3.1  Lupus Erythematosus
Cases of lupus erythematosus, both subacute and chronic, 
have been attributed to the exposure to exogenous drugs/
allergens and the sun. Most patients have anti-Ro auto-
antibodies, the hallmark of photosensitivity in lupus ery-
thematosus. Lesions develop weeks or months after 
exposure on the exposed areas of face, neck, upper chest, 
and arms, as erythematosus and scaling annular lesions 
typical of subacute lupus erythematosus or, more rarely, 
chronic lesions on the face or V of the neck [14]. This 
was described initially for thiazide diuretics, calcium 
channel blockers, ACE inhibitors [54], terbinafine [55], 
and recently from the anticancer taxanes, paclitaxel, and 
docetaxel [36, 56]. The drugs may enhance UV-induced 
expression of the Ro antigen on the surface of keratino-
cytes, interfere with apoptosis or cytokine production, 
thereby promoting photosensitivity and the development 
of skin lesions in susceptible individuals [54].
18.3.3.2  Chronic Actinic Dermatitis
Chronic actinic dermatitis, more common in older 
men, can present as a photosensitive eczema or, more 
frequently, like a long-lasting chronic eczema with a 
brown–gray hyperpigmentation, skin edema, licheni-
fication that resemble its lymphomatoid variant, and 
actinic reticuloid (Fig. 18.4). Also, on histology, large 
activated lymphocytes in the dermis mimic lym-
phoma. Lesions are localized on the photoexposed 
areas (face, sides and back of the neck, upper chest, 
and dorsum of the hands and forearms) and are aggra-
vated by sun exposure; even this may not be very 
apparent because of the small amounts of UV neces-
sary to aggravate the lesions. The hallmark of this dis-
ease is the extreme photosensitivity, even on covered 
areas, to UVB (reduced MED) and, often, also UVA 
and visible light [7, 57].
In many cases, these patients have previously suf-
fered from an idiopathic photodermatosis, a chronic 
photodermatitis or, more frequently, from an airborne 
allergic contact dermatitis from perfumes, sesquiter-
pene lactones from Compositae, or colophony from 
conifers, and in its evolution, they become extremely 
photosensitive even with no further exposure to an 
exogenous chromophore or allergen. An autoantigen 
(DNA or RNA modified by plant products or another 
autoantigen) may have been formed during the acute 
reaction or, may be the regular UV-induced immuno-
suppression did not work correctly and individuals 
were sensitized to this new autoantigen and devel-
oped a reaction similar to allergic contact dermatitis 
[17, 57].
18.3.3.3  Enhancement of Photocarcinogenesis
Recent reports are documenting the relation between 
exposure from photoactive molecules and increasing 
incidence of actinic keratosis or squamous cell carci-
noma, in a parallel of what was observed with long time 
therapeutic exposure to PUVA. Apart from psoralens, 
naproxen, chlorpromazine, and the fluorquinolones, 
particularly lomefloxacin, also have the capacity to 
induce DNA aggression upon UV exposure, in vitro, 
and to increase epidermal neoplasia in animals [8, 9]. 
This concern may have to be taken into account, namely 
as severe photosensitivity associated with skin cancer 
has been observed with voriconazole [16] and cipro-
floxacin (personal experience) and epidemiological 
studies seem to correlate exposure to photoactive drugs 
and an increase in the risk of developing actinic kera-
toses, nonmelanoma skin cancer and, even, malignant 
melanoma [13, 15]. Also, photoaging may be enhanced 
by the exposure to topical or systemic photosensitizers.
18.4  Main Topical and Systemic 
Photosensitizers
There is a large and increasing list of photoactive mol-
ecules to which we can be exposed to in our daily life 
and which can induce photosensitivity. But there has 
been increasing concern on the evaluation of the photo-
toxic potential, particularly of cosmetics and consumer 
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18 Phototoxic and Photoallergic Reactions 
products, and very important photosensitizers have been 
eliminated or highly reduced in our ambience. These 
“historical” photosensitizers are musk ambrette and 
natural bergamot oil, removed by the perfume industry; 
the sunscreen isopropyldibenzoylmethane, withdrawn 
in 1994; the antibiotic olaquindox, a swine feed additive 
banned in 1998 by the European Commission [58]; and 
the halogenated salicylanilides removed from disinfec-
tants and hygiene products in most countries since 1976. 
Nevertheless, even though some products are not avail-
able in Europe, they can be “imported” from other 
countries and induce photosensitivity [58, 59].
In most reports, the main topical photosensitizers 
are the UV filters [3, 60, 61], which represent 56–80% 
of the cases diagnosed by photopatch testing [3, 62–64]. 
Furocoumarins from plants are an important source of 
photosensitivity, mainly in more sunny countries, and 
drugs are, by far, the most frequent photosensitizers in 
Southern Europe [62, 64–66].
18.4.1  UV Filters
Due to the increased awareness of the sun damaging 
effects, sunscreens are used in large amounts and UV 
filters are also present in cosmetics, like moisturizing 
and facial creams, lipstick, nail varnish, shampoos, and 
other hair products. Apart from protecting the skin and 
hair from solar aggression, they are intended to prevent 
the degradation of the product by the sun and, there-
fore, increase its shelf half life. But, happily, concur-
rent with this high use, adverse skin reactions from UV 
filters are not reported so frequently [3]. In recent stud-
ies, positive photopatch tests or photoaggravated reac-
tions to UV filters occurred in 5.7–12% of a total of 
about 2,400 patients tested [4, 62, 64–67].
The newer UV filters – Mexoryl SX (terephtalydene 
dicamphor sulfonic acid), Tinosorb M (methylene-
bis-benzotriazolyl tetramethylbutylphenol or bisoctri-
zole), and Tinosorb S (bis-ethylh exyloxyphenol 
methoxyphenyl triazine) – are photostable molecules 
and, in mixtures of several sunscreens, are able to sta-
bilize older photo labile UV filters, like butyl meth-
oxydibenzoylmethane and cinnamates. Therefore, they 
seem to be more efficient in protecting the skin from 
the harmful effects of UVR [68] and eventually in 
reducing photoallergic dermatitis, even from the other 
UV filters. Apparently, a single case of photoallergy 
was reported from Mexoryl SX [60] with no cases of 
photoallergy from Tinosorb M or S. There are only 
very rare cases of allergic contact dermatitis from the 
surfactant decylglucoside that is used to solubilize the 
active molecule of Tinosorb M [69, 70].
The other UV filters have been responsible for aller-
gic contact and/or photocontact dermatitis, or photoag-
gravated contact dermatitis [4]. In the 50s and 60s, 
PABA (p-aminobenzoic acid) was responsible for 
many cases of allergic and photoallergic contact der-
matitis (4% of the population in an American study) 
[68] and, therefore, since then it was seldom used. 
Nevertheless, a very recent case of photoallergic con-
tact dermatitis was published [59].
In the studies from the 70s till the end of the 90s, 
most frequent photosensitizers are the UVA filters, oxy-
benzone (benzophenone 3), and isopropyldibenzoyl-
methane [31, 63, 64, 67, 71]. At present, the latter is not 
produced anymore, and the other dibenzoylmethane on 
the market, butyl methoxydibenzoylmethane, is not such 
a potent photosensitizer. Many reactions previously 
reported were probably due to a cross-reaction [71].
Oxybenzone, still the most used UV filter, is being 
replaced in many sunscreens. Those sunscreens having 
a concentration higher than 0.5% must print a warn-
ing on the label. Nevertheless, in this setting or as a 
common ingredient in cosmetics, oxybenzone is still 
the most frequently used UV filter responsible for pos-
itive photopatch tests [4, 60, 64, 67]. Rarely, it can also 
induce contact photocontact urticaria or anaphylaxis 
[32]. Sulisobenzone (benzophenone 4) and mexenone 
(benzophenone 10) induce allergic or photoallergic 
contact dermatitis less frequently [64, 72, 73].
Another concern on oxybenzone, and the other ben-
zophenones, is related to its percutaneous absorption 
and its environmental spread, which may be harmful 
due to its potential estrogen-like effects [74].
Cinnamates, namely isoamyl-p-methoxycinnamate 
and ethylhexyl-p-methoxycinnamate, and 4-methyl-
benzylidene camphor, phenylbenzimidazole sulfonic 
acid, drometrizole trisiloxane (Mexoryl XL) and octyl 
dimethyl PABA (Padimate O) are also regularly respon-
sible for cases of photoallergy [3, 4, 62, 64, 66, 67]. 
Other UVB filters, namely the salycilates (octylsaly-
cilate and homosalate) and octocrylene are seldom 
reported to cause allergic or photoallergic contact der-
matitis [75, 76], except in an Italian study where 
octocrylene was the most frequent UV filter responsi-


































































































18.4.2  Plants Causing 
Phytophotodermatitis
Photoactive furocoumarins, e.g., bergapten, 5- and 
8-methoxypsoralen, run in the sap of several plants, in 
variable amounts, as a protection against fungus and 
insects. Since the antiquity, these substances have been 
used in folk Medicine (vitiligo) and, more recently, in 
photochemotherapy (PUVA), and the aromatic oils rich 
in furocoumarins were used by the cosmetic industry in 
tanning oils and perfumes. As UV-induced skin pigmen-
tation was proved to be a marker for DNA aggression, 
the use of tanning oils has been considerably reduced, 
and the natural bergamot oil responsible for “Berloque 
dermatitis” from perfumes is no more used [77].
Dermatitis can also occur from inadvertent contact 
with these plants, both during recreation or in an occu-
pational setting, e.g., rural workers or gardeners who 
harvest fruits or vegetables (parsnip, figs) or cut bushes 
and weeds (common rue – Ruta graveolans – burning 
bush – Dictamus albus – or fig trees – Ficus carica) 
[77, 78], or barmen who squeeze and peal lime (Citrus 
aurantifolia) and other citrus fruits to prepare cocktails 
in the sunny weather [77, 79, 80] (Fig. 18.5).
The most typical pattern of phytophotodermatitis was 
described by Oppenheim in 1934 – dermatosis bullosa 
striata pratensis. Linear streaks, corresponding to the 
contact with the damaged leaves of the plant, begin 
within 24–48 h with prickling erythema and, later, pain-
ful vesicles and bullae (Fig. 18.6). All these gradually 
give rise to long-lasting linear hyperpigmentation, which, 
sometimes, allows a retrospective diagnosis [80].
Another pattern is the “strimmer dermatitis” with a 
diffuse involvement as the sap of the plant is sprayed 
all over by the string trimmer [77]. Children who play 
in nature were more prone to this dermatitis and, very 
particularly, those making trumpets or pea shooters 
from the hollow stems of the giant hogweed (Heracleum 
mantegazzianum) developed blisters around their mouth 
[77]. Very occasionally, the ingestion of these plants 
can induce a systemic photosensitivity as in the cases 
of celery, parsnip, or infusions of St. John’s wort 
(Hypericum perforatum L.) used to treat depression 
[77, 81].
Plants rich in furocoumarins causing phytophoto-
dermatitis occur all over the globe and belong mainly 
to the families of Umbelliferae, Rutacea, and Moracea 
(Table 18.3).
Fig. 18.5 Residual pigmentation in the forearms in a barman 
who had been squeezing limes and lemons for cocktails, during 
an outdoor summer festival (note limit due to glove protection)
Fig. 18.6 Phytophotodermatitis with linear streaks of erythema 
and bullae in the arms of a patient who had been cutting a fig tree 
during a sunny afternoon
Core Message
UV filters in sunscreens or cosmetics are the  ›
















































18 Phototoxic and Photoallergic Reactions 
18.4.3  Photosensitive Drugs
According to the results of the photopatch series in 
Southern European countries, drugs are by far the main 
cause of exogenous photoallergy, whereas in the 
Northern countries sunscreens occupy the first rank as 
photosensitizers [62, 64–66]. This may be due to dif-
ferent prescription habits or because NSAIDs, the main 
drugs responsible for positive photopatch tests, were 
not regularly included in most photopatch test series.
Drugs used systemically, applied topically, or han-
dled in an occupational setting can induce photosensi-
tivity. Carprofen, a NSAID no more used in humans, 
induced photoallergic contact dermatitis in workers 
who manufacture the drug for animals [82, 83]. Also, 
we observed cases of photosensitivity in nurses and 
family members who had to smash the tablets of chlor-
promazine to give to their patients/relatives [62].
Systemically, antimicrobials, particularly tetracyclines, 
fluorquinolones, sulfonamides, and some antifungals 
(voriconazole, griseofulvin), NSAIDs, phe nothiazines, 
and cardiovascular drugs are mainly re spon sible for pho-
tosensitivity, whereas after topical application, NSAIDs 
are by far the most frequent cause [62, 64–66].
18.4.3.1  Antimicrobials
Systemic tetracyclines, particularly doxycycline and 
minocycline, are highly phototoxic and induce photo-
onycholysis and pseudoporphyria and, the latter can 
also induce a bluish persistent pigmentation [51, 52] 
(Fig. 18.4).
The fluorquinolones induce phototoxic reactions, 
in some cases presenting as pseudoporphyria [40], as 
initially described for the first quinolone antibiotic, 
nalidixic acid [51], or as purpura in a case by cipro-
floxacin [53]. Phototoxicity is particularly important 
and frequent (4–15% of treated patients) with fleroxa-
cin, lomefloxacin, sparfloxacin, and pefloxacin and 
less frequent with ciprofloxacin, norfloxacin, ofloxa-
cin, and enoxacin [14]. This can be reduced with drug 
intake by the end of the day, to reduce drug concen-
trations in the circulation and in the skin during the 
midday. Photoallergy has also been reported with 
lome floxacin [20, 21] and enoxacin [51], sometimes 
with cross-reaction to other fluorquinolones (cipro-
floxacin and flerofloxacin) [84, 85]. Experimental 
[AU4]
Sunscreens
 Benzophenones: oxybenzone, sulisobenzone, mexenone
 Dibenzoylmethanes: butyl methoxydibenzoylmethane
  Cinnamates: isoamyl-p-methoxycinnamate, ethylhexyl 
methoxycinnamate
 PABA and analogs: p-aminobenzoic acid; padimate O
  Other: 4-methylbenzylidene camphor, phenylbenzimidazole 
sulfonic acid, octocrylene, drometrizole trisiloxane
Plants (main Families in Europe)
  Umbelliferae: Ammi majus, Apium graveolens (celery), 
Pastinaca sativa (parsnip), Petroselinum crispum (parsley), 
Heracleum mantegazzianum (giant hogweed)
  Rutacea: Citrus spp, Citrus aurantica v. bergamia (berga-
mot), Citrus aurantifolia (lime), Citrus limon (lemon), Ruta 
graveolans (common rue), Dictamus albus (burning bush)
 Moracea: Ficus carica (fig)
Drugs (see details in Table 18.4)
“Historical” photosensitizersa
 Perfumes: musk ambrette and bergamot oil
  Halogenated salicylanilides: tetrachlorsalicylanilide, 
trichlorocarbanilide, tribromsalicylanide
 Sunscreens: isopropyldibenzoylmethane, PABA
 Antibiotics: olaquindox
 Dyes: eosin, acridine orange, and acriflavin
Table 18.3 Main agents causing exogenous photosensitivity
aAlthough “historical,” some still induce photoallergic contact der-
matitis
Core Message
 › Dermatosis bullosa striata pratensis, with lin-
ear lesions that regress with hyperpigmenta-
tion, is a phototoxic dermatitis from psoralen 
rich plants.
Core Message
Topical NSAIDs (ketoprofen) and systemic  ›
antibiotics (fluorquinolones, tetracyclines) can 











































































studies proved the photoallergenicity of fluorquinolo-
nes, with positive lymphocyte stimulation tests and 
drug specific Th1 cells that recognize skin cells com-
bined with UV-irradiated ofloxacin [86]. The fluor-
quinolones also photosensitize DNA and may be 
photo mutagenic and photocarcinogenic [8]. We had 
the opportunity to observe a patient on long-term cip-
rofloxacin therapy for multiresistent tuberculosis, 
who developed photosensitivity and highly aggres-
sive squamous cell carcinomas on the face.
Sulphonamide antibacterials, as well as sulfa-drug 
analogs (thiazidic diuretics, hypoglycemic sulfonylu-
reas, and celecoxib) and dapsone (diamidiphenylsul-
fone), have been reported to cause photosensitivity 
within the spectrum both of UVB and UVA [51, 87, 88], 
but this side effect is not so frequent with the most cur-
rently used cotrimoxazole (trimethoprim/sulfamethox-
azole) [14, 51].
Griseofulvin is a known phototoxic drug and can 
aggravate lupus erythematosus, as the more recent anti-
fungal, terbinafine, which also induced subacute lupus 
erythematosus in patients with anti-Ro antibodies [55]. 
Another antifungal, still from a different chemical 
group, voriconazole, has recently been reported to 
cause severe photosensitivity [7] and was considered 
responsible for skin cancer [16, 28, 43].
18.4.3.2  Nonsteroidal Anti-Inflammatory Drugs
Benoxaprofen marketed between 1980 and 1982 called 
the attention to photosensitivity from this class of drugs. 
Thereafter, all the other arylpropionic derivatives (car-
profen, naproxen, suprofen, tiaprofenic acid, ketoprofen, 
ibuprofen) and NSAIDs from other groups (azapropa-
zone, diclofenac, piroxicam, fenilbutazone, celecoxib, 
benzydamine, etofenamate) have been shown to cause 
photosensitivity [39].
Most topically applied NSAIDs are absorbed 
through the skin and cause distant lesions, resembling 
systemic photosensitivity. Benzydamine, widely used 
in the oral or genital mucosa, causes photosensitivity 
at distant sites [89], eventually after systemic absorp-
tion [29, 65] and, when used in the mouth, can induce 
cheilitis and chin dermatitis as a manifestation of pho-
toallergy [29, 62].
Although not the most sold, ketoprofen and piroxi-
cam cause most cases of photosensitivity [62, 64, 
65, 90]. Contrary to most other drugs, photoallergy is 
mainly involved with very particular patterns of cross-
reactivity.
Ketoprofen
Ketoprofen, particularly when used topically, is respon-
sible for severe photoallergic reactions [7, 91], often 
with edema, bullae or erythema multiform, extending 
well beyond the area of application [34, 35, 92], due to 
contamination of the hands or other personal objects or 
due to systemic absorption [92]. Reactions may recur 
on sun exposure with no apparent further drug applica-
tion [34, 91], but they do not fulfill the criteria for the 
diagnosis of persistent photosensitivity. Some may be 
explained by persistence of the drug in the skin (at least 
17 days) [92] by contact with previously contaminated 
objects, even after washing [26], or from exposure to 
cross-reactive chemicals [34].
Although such a high frequency might suggest pho-
totoxicity, the clinical pattern with erythema multiform, 
positive lymphocyte stimulation tests with ketoprofen 
photomodified cells, animal studies with the absence of 
phototoxic potential [93], the capacity to photosensitize 
and transfer photoallergy by T-cells, both CD4 and CD8 
exhibiting chemokine receptors for Th1 and Th2, 
in vitro activation and maturation of antigen-presenting 
cells by ketoprofen and UVA, [35, 94, 95], and charac-
terization of a stable photoproduct – 3-ethyl-benzophe-
none [34, 96] – highly support a photoallergic reaction.
Cross-reactions occur between arylpropionic acid 
derivatives that share the benzophenone radical, namely 
tiaprofenic acid and suprofen, and are not extensive to 
naproxen or ibuprofen. As that radical is common to 
the benzophenone UV filters, cross-reactions are com-
mon with sunscreens containing mainly oxybenzone 
[96]. A similar structure is present in the systemic 
hypolipemic agent, fenofibrate, that also induces sys-
temic photosensitivity with cross-reactions with keto-
profen [62] and, in patients taking this drug, it was a 
risk factor for more severe photoallergic contact der-
matitis from ketoprofen [91, 96].
These patients have a higher reactivity, in patch 
tests, to balsam of Peru and perfume mix I, particularly 
cinnamic aldehyde [34, 97], still not completely 
explained.
Analogs of ketoprofen, piketoprofen, and dexketo-
profen also cause photosensitivity with cross-reactivity 






























































































18 Phototoxic and Photoallergic Reactions 
Piroxicam
Piroxicam is a well-known photosensitizer since the 
80s. Although there was some enigma to explain this 
photosensitivity at the beginning [100], soon a relation 
was established with contact sensitivity to thiomersal 
[101, 102], more precisely to thiosalicylic acid [24], one 
of the sensitization moieties most frequently responsi-
ble for contact allergy to thiomersal [103]. Actually, 
upon low UVA irradiation, piroxicam decomposes and 
gives rise to a photoproduct structurally similar to 
thiosalicylic acid, UVA-irradiated solutions of piroxi-
cam induce positive patch tests in thiosalicylic allergic 
patients [24, 39, 103, 104], animals sensitized by 
thiosalicylic acid develop photosensitivity from piroxi-
cam, and their lymphocytes are stimulated both by 
thiosalicylic acid and by piroxicam, in the presence of 
UVA [25].
Photoallergy from piroxicam can occur both from 
topical application and systemic use and, although it is 
becoming less frequent, probably because of the replace-
ment of this NSAIDs by the newer drugs [23], it is still 
observed in Southern Europe [29, 64–66].
Systemic photosensitivity usually occurs within 
24–48 h after the first drug intakes, as the individuals 
have been previously been sensitized though thiomersal. 
It can present as an acute eczema involving diffusely the 
whole face (Fig. 18.2) or, often, as scattered erythemato-
sus papules and vesicles on the face and dorsum of the 
hands and dyshidrosis [19, 23, 105, 106]
These patients do not react, neither on photopatch 
nor on drug rechallenge, to tenoxicam, meloxicam, or 
lornoxicam, as these oxicams do not share the thiosali-
cylate moiety [24, 107]. Nevertheless, it is important to 
remember that cross-reactivity between piroxicam and 
these oxicams occurs regularly in fixed drug eruption 
[108, 109].
18.4.3.3  Other Drugs as Photosensitizers
Phenothiazines used systemically (chlorpromazine 
and thioridazine) can induce photosensitivity, often 
with a lichenoid pattern and with residual pigmenta-
tion [52] (Fig. 18.3). Promethazine, still being used as 
a topical antipruritic, at least in Portugal, Greece, and 
Italy [62, 66, 110], and its analog chlorproethazine, 
which is being marketed in France as Neuriplege® 
cream for muscle pain (Genevrier, Antibes, France) 
are frequent causes of photoallergic contact dermatitis 
in these countries [111, 112].
The list of drugs causing photosensitivity is very 
large and always increasing; therefore, whenever a 
patient has a photosensitive eruption a systematic inquiry 
for drugs should be carefully conducted (Table 18.4). 
The complementary methods for its diagnosis, photo-




 Tetracyclines (doxycycline, minocycline)
 Sulphonamides (sulfamethoxazole)
 Fluorquinolones (lomefloxacina, ciprofloxacina)
 Voriconazole, griseofulvin
 Efavirenz
Nonsteroidal anti-inflammatory drugs (NSAIDs)
Arylpropionic acids









 Clomipramine, imipramine, sertraline
Cardiovascular drugs
 Amiodarone, quinidine
 Furosemide and thiazide diuretics
Anticancer agents




Table 18.4 Main drugs causing exogenous photosensitivity
aInduce photoallergic and allergic contact dermatitis
bAlthough phototoxic, can induce photoallergic reactions
cInduces mainly systemic photoallergy

























































































Phototoxic and photoallergic reactions are still a frequent 
problem, with a highly polymorphic clinical presenta-
tion and variations in the responsible agents according to 
geographical areas, and along the years, as new photo-
sensitizers come into the market whereas others are 
abandoned. Therefore, we must be highly alert to sus-
pect the involvement of an exogenous chromophore in a 
photosensitive patient, to conduct the questionnaire in 
this sense, and to proceed to further complementary tests 
to prove such a diagnosis and, consequently, advise the 
patient concerning further eviction of the photosensitizer 
and related chemicals.
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Query Details Required Author’s Response
AU1 Technical terms have been spelled wrongly in many instances. We have corrected them. Please 
check the same.
AU2 Please check whether the edited table18.2 is appropriate.
AU3 Please check whether the edit is ok.
AU4 In the sentence, ‘Systemically, antimicrobials...’ please check if the insertion of the words ‘for 
photosensitivity’ is appropriate. 
AU5 Please confirm this deletion.
AU6 Please mention the appropriate year.
